BACKGROUND: Endomorphin-1 and endomorphin-2 are endogenous peptides that are highly selective for -opioid receptors. However, studies of their functional efficacy and selectivity are controversial. In this study, we systematically compared the effects of intrathecal (i.t.) administration of endomorphin-1 and -2 on nociception assays and G protein activation with those of [d-Ala 2 ,N-Me-Phe 4 ,Gly 5 -ol]-enkephalin (DAMGO), a highly effective peptidic -opioid receptor agonist. METHODS: Male Sprague-Dawley rats were used. Acute and inflammatory pain models were used to compare the duration and magnitude of antinociception. Agonist-stimulated [
The-opioid receptors are G protein-coupled receptors that play a pivotal role in the analgesic effects of opioid receptor agonists used clinically. 1, 2 Given that intrathecal (i.t.) administration of opioids is one of the most frequently used methods of analgesia in humans, [3] [4] [5] it is important to study the functions of spinal -opioid receptors. In particular, the peptidic -opioid receptor agonists are of interest due to their enzymatic degradation and low toxicity. 6 Endomorphin-1 and endomorphin-2 are endogenous opioid peptides isolated from bovine and human brains, and both peptides have high affinity and selectivity for -opioid receptors. 7, 8 Endomorphins have been implicated in a broad range of physiological functions including antinociceptive, cardiovascular, respiratory, digestive, rewarding, and endocrine responses. 9, 10 One important issue is the efficacy of endomorphins in activating -opioid receptors and subsequent antinociceptive effects manifested in vivo. Previous studies measuring the degree of agoniststimulated G protein activation have shown that endomorphins act as partial agonists in the mouse spinal cord membranes and cell lines expressing -opioid receptors. 11, 12 In contrast, other studies indicate that endomorphins are full agonists in the rat thalamic membranes and cell lines expressing -opioid receptors. 13, 14 Although the antinociceptive effects of spinally administered endomorphins have been studied in rodents, [15] [16] [17] [18] there are few studies that directly compare the relative degrees, potencies, and durations of antinociceptive effects of i.t. endomorphins with those of i.t. [d-Ala, 2 N-Me-Phe, 4 Gly
5
-ol]-enkephalin (DAMGO), a highly effective peptidic -opioid receptor agonist. 17 In particular, there is no study using both in vivo and in vitro measurements at the same time to compare the intrinsic efficacy between endomorphins and DAMGO at the rat spinal -opioid receptors.
Therefore, the aim of the study was to systematically investigate and directly compare the spinal antinociceptive effects of DAMGO, endomorphin-1, and endomorphin-2 together in rats by using both in vitro and in vivo assays. Agonist-stimulated [ 35 S] guanosine-5Ј-O-(3-thio)triphosphate (GTP␥S) binding 19 -22 was used to observe the functional activity at the level of the receptor-G protein in both spinal cord and thalamic membranes. Acute and inflammatory pain models 23, 24 were used to determine the degree of antinociceptive effects of these peptidic agonists after i.t. administration. With additional antagonist studies, this study used a pharmacological approach to elucidate the relative efficacy and functional selectivity of endomorphins as antinociceptive agents in the spinal cord of rats.
METHODS

Animals
Male Sprague-Dawley rats (275-300 g) were obtained from Harlan (Indianapolis, IN) and were housed in groups of three rats per cage. All animals were allowed ad libitum access to food and water, and were maintained on a 12 h light/dark cycle with lights on at 06:30 am in a room kept at a temperature of 22°C Ϯ 1°C. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. The experimental protocols were approved by the University Committee on the Use and Care of Animals at the University of Michigan.
Procedure
Intrathecal Catheterization For i.t. administration, the rat was implanted with an i.t. catheter (see details for surgery in Zhang et al. 25 ). After surgery, rats were housed individually and allowed 6 -7 days for recovery. Lidocaine (2%, 10 L) was administered i.t. to confirm whether the catheter was in the correct position. Lidocaine produces a transient paralysis of the hindpaws when it is injected into the lumbar enlargement. Rats were not used in the behavioral study if they did not show paralysis after receiving i.t. lidocaine or they showed motor dysfunction. For the behavioral study, a 10-L solution of the test compound was infused, followed by an additional 10 L of saline for flushing the catheter over a 30-s period. In addition, the i.t. catheter placement was verified after each experiment by administering methylene blue and checking for the distribution within the lumbar subarachnoid space. Only data obtained from rats with good i.t. catheter placement were used for data analysis. The dose ranges of i.t. DAMGO (0.01-0.3 g), endomorphin-1, and -2 (3-30 g), were chosen based on previous studies, showing that these doses produced maximal behavioral effects without producing behavioral toxicity. 16, 26 It should be noted that 100 g of i.t. endomorphin-1 and -2 produced motor impairment in our pilot studies.
Warm Water Tail-Withdrawal Assay
The antinociceptive effect was measured by using a warm water tail-withdrawal assay, which was similar to the study by Walker et al. 23 Briefly, 1 wk before the test, rats were habituated to the restraint tubes three times. The rat was placed into a restraint tube with its tail hanging freely. The last 5-7 cm of the tail was immersed into thermocontainers with either 40 (innocuous) or 55°C water (noxious stimulus), and the latency for tail withdrawal was measured. A cutoff time of 15 s was imposed to prevent tissue damage, and each stimulus presentation was separated by a 2-min interval. Baseline/control latencies of tail withdrawal in both 40°C and 55°C water were obtained for each rat 10 min before i.t. administration of the test compound. Then, the latency to withdraw the tail was re-determined at 10, 20, 30, 45, 60, and 90 min after i.t. administration.
Formalin Nociceptive Assay
Formalin was used to elicit nociceptive responses (i.e., hindpaw flinches) for measuring the antinociceptive effect of the test compound. 24 Briefly, rats were placed individually in Plexiglas observation chambers (55 cm long ϫ 30 cm wide ϫ 26 cm high) and allowed to habituate for at least 15 min. A mirror was placed behind the chamber, which provided a clear view of the rat's paw movement. Each rat received an injection of 2% formalin in 50 L subcutaneously into the dorsal surface of the right hindpaw, returned to the observation chamber, and numbers of flinches were recorded by individuals who did not know the experimental condition. The test compound was given i.t. 5 min before formalin injection; then effects of the test compound to inhibit formalin-induced flinches were measured. Flinching responses were scored in a 5-min interval for 40 min and manifested for two characteristic time periods; i.e., 0 -10 min (phase 1) and 11-40 min (phase 2) after formalin administration.
Agonist-Stimulated [
35 S]GTP␥S Autoradiography Agonist-stimulated [ 35 S]GTP␥S autoradiography was performed as described previously. 21 Briefly, coronal sections (20 m) were cut in the lumbar enlargement of the spinal cord of the naïve rat on a cryostat maintained at Ϫ18°C, mounted on gelatinsubbed slides, and stored at Ϫ80°C for Ͻ4 wk after collection. The sections were rinsed in the assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, and 0.1% bovine serum albumin, pH 7.4) for 10 min at 25°C, followed by preincubation in the assay buffer containing 2 mM GDP and 9.5 mU/mL adenosine deaminase for 15 min at 25°C. Then, sections were incubated in the assay buffer with GDP, adenosine deaminase, 0.04 nM [
35 S] GTP␥S, and 10 M of an agonist (i.e., DAMGO, endomorphin-1, or endomorphin-2) for 2 h at 25°C. Basal G protein activation was determined by incubating sections without agonists, and nonspecific binding was determined by adding 10 mM unlabeled GTP␥S. After 2-h incubation, slides were rinsed twice for 2 min in ice-cold 50 mM Tris buffer (pH 7.4) and once in distilled water for 1 min. Slides were air-dried for a few hours and exposed to film for 48 h in film cassettes together with 14 C Microscale standards (Amersham Biosciences Inc., Piscataway, NJ) for densitometric analysis. Then the films were developed using an autoprocessor. The slices were scanned at 600 dpi for analysis. Images were digitized and densitometric analysis was conducted by using NIH Image J software. Optical density measurements were converted to [ 35 S]GTP␥S binding values (nCi 35 S per gram of tissue) by use of the 14 C standards and a conversion factor. 21 All three compounds were tested on eight spinal cord sections per rat in six rats.
Agonist-Stimulated [ 35 S]GTP␥S Binding in Membranes
The membranes of thalamus and spinal cords were isolated from rats. Tissues were homogenized in 20 volumes (w/vol) of ice-cold Tris-HC1 buffer (50 mM, pH 7.4) and centrifuged at 15,000g, 4°C, for 20 min. The pellet was resuspended in Tris-HCl buffer and incubated for 15 min at 37°C. Centrifugation was repeated and the final pellet resuspended in Tris-HCl buffer and stored in aliquots at Ϫ80°C. The [ The incubation was terminated by filtrating the samples through the glass fiber filters. Filters were washed three times with ice-cold buffer (Tris 50 mM, MgCl 2 5 mM, 100 mM NaCl, pH 7.4) in a Millipore filtration instrument, dried, and measured for their liquid scintillation counting. Each data point was subtracted by the basal value and converted to femtomoles per milligram of protein to determine agoniststimulated [ 35 S]GTP␥S binding. Two thalamic and two spinal membrane preparations from a rat were tested in each binding experiment, and the experiment was repeated at least three times for each rat.
Drugs DAMGO, endomorphin-1, endomorphin-2, naltrexone, naltrindole, and NLX (National Institute on Drug Abuse, Bethesda, MD) and nor-binaltorphimine (SigmaAldrich, St. Louis, MO) were dissolved in sterile water. [ 35 S]GTP␥S (1250 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA). GDP and all other biochemicals were purchased from Sigma Chemical. For the antagonist study in vivo, rats were injected with either sterile water (vehicle, 1 mL/kg), naltrexone (0.1 mg/kg) or naltrindole (3 mg/kg) subcutaneously 30 min before an i.t. administration of the agonist. Nor-binaltorphimine (10 mg/kg) was injected subcutaneously 24 h before the i.t. administration of the agonist. The dose and pretreatment time for these opioid receptor antagonists were chosen based on previous studies showing that naltrexone, naltrindole, and norbinaltorphimine produced selective functional antagonism for -, ␦-, and -opioid receptors, respectively.
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Data Analysis
All data were expressed as mean Ϯ sem from individual values for all behavioral end-points. The tail-withdrawal latencies were converted to a percentage of maximum possible effect (%MPE) by the formula: %MPE ϭ (test latency Ϫ control latency)/(15 s Ϫ control latency) ϫ 100, using the control baseline latency in 55°C water measured at the beginning of each experiment. Data for the time course and total flinching responses were analyzed by a two-way analysis of variance, followed by the Dunnett test for multiple post hoc comparisons (*P Ͻ 0.05 for significance). ED 50 values were calculated by least-squares regression with the portion of the dose-response curves that spanned 50% of responding. For the [ 35 S]GTP␥S binding experiments, data were analyzed by a sigmoidal curve with a variable slope using GraphPad Prism (GraphPad Software Inc., San Diego, CA) to determine the EC 50 value and maximum stimulation. The criterion for significance was also set at P Ͻ 0.05. Figure 1 illustrates the degree and time course of antinociception produced by i.t. administered DAMGO, endomorphin-1, and endomorphin-2 in the warm water tail-withdrawal assay. There was no difference in the baseline tail-withdrawal latency among groups. All rats' baseline withdrawal latencies in 40°C water were 15 s. The mean values of baseline withdrawal latencies in 55°C water in different groups ranged from 2.6 Ϯ 0. In contrast, the antinociceptive effects of both endomorphins at 30 g lasted for 20 -30 min after i.t. administration. The mean values of each agonist's potency and magnitude in producing antinociception are summarized in Table 1 . Figure 2 illustrates the effects of opioid receptor antagonists on the antinociception of i.t. administered endomorphins in the warm water tail-withdrawal assay.
RESULTS
Post hoc
endomorphin-induced antinociception (P Ͼ 0.05). Figure 3 illustrates the degree and time course of antinociception produced by i.t. administered DAMGO, endomorphin-1, and endomorphin-2 in the formalin nociceptive assay. I.t. administration of DAMGO [F (44, Table 1 . Figure 4 illustrates the effects of opioid receptor antagonists on the antinociception of i.t. administered endomorphins in the formalin nociceptive assay. Post hoc comparisons indicated that only pretreatment with naltrexone 0.1 mg/kg significantly reversed antinociception of i.t. endomorphin-1 and endomorphin-2 in both phases (P Ͻ 0.05). Neither naltrindole nor norbinaltorphimine antagonized i.t. endomorphinsinduced attenuation of formalin-induced flinching responses (P Ͼ 0.05). Table 2) . Addition of NLX (20 nM) produced approximately 8 -10 fold rightward shifts in the concentration-response curves of DAMGO, endomorphin-1 and endomorphin-2 ( Table 2) . Similarly, the degree of DAMGO-stimulated [ 35 S]GTP␥S binding was significantly higher than those by endomorphins in the rat thalamic membranes. Addition of NLX (20 nM) also produced approximately 8 -10 fold rightward shifts in the concentration-response curves of DAMGO, endomorphin-1, and endomorphin-2 in the thalamic membranes (Table 2 ).
DISCUSSION
The behavioral study showed that i.t. endomorphin-1 and endomorphin-2 were less potent and produced less antinociceptive effects than i.t. DAMGO in the rat model of acute pain ( Fig. 1 and Table 1 ). The doses of i.t. endomorphin-1 and -2 used in this study were similar to those reported by other researchers using different types of pain models. 16, 17 However, these early studies did not thoroughly compare the degrees of antinociception produced by i.t. endomorphins with that of DAMGO, a highly effective peptidic -opioid receptor agonist. The degree of antinociceptive effects measured herein may depend on the intensity and modality of noxious stimuli. 31, 32 Nevertheless, by using the same noxious stimulus (i.e., 55°C water) in rats, the present study demonstrates that i.t. administration of endomorphins act as partial agonists for antinociception in vivo as compared with i.t. DAMGO.
The functional study of G protein activation in the rat spinal cord further supported the different degrees of intrinsic efficacy between endomorphins and DAMGO. The [
35 S]GTP␥S binding assay and autoradiography both revealed that endomorphin-1 and -2 produced less G protein activation in the rat spinal cord and thalamus (Figs. 5 and 6 ). Such a finding is consistent with those reported in previous [ 35 S]GTP␥S binding studies using different brain membranes or cell lines. 11, 12, 21 However, this finding is different from a study showing that endomorphins and DAMGO had similar efficacy in stimulating [ 35 S]GTP␥S binding in the rat thalamic membranes. 14 The magnitudes of opioid agonist-induced [ 35 S]GTP␥S binding may depend on the receptor density in a specific region of the central nervous system. 21, 22, 33 Therefore, the large amount of membranes (e.g., 100 vs 10 g) used in one study 14 may saturate the measurement of GTP␥S binding and reduce the potential differences of efficacy measurement among tested ligands. Nevertheless, the present findings are consistent with most in vitro studies, indicating that endomorphin-1 and -2 are partial agonists for G protein activation at the -opioid receptors. 11, 12, 21 The degree of antinociception produced by spinal opioids depends on the agonist's intrinsic efficacy and the intensity of the nociceptive stimulus. 34, 35 For example, high efficacy -opioid agonists produce maximal effects in antinociceptive assays using both low-and high-intensity nociceptive stimuli, whereas the maximal effects of low efficacy -opioid agonists decrease when the intensity of the nociceptive stimulus increases. 31, 32, 34, 35 The present study could not test a higher dose of endomorphins due to observed side effects 16 ; thus, it may be difficult in vivo to demonstrate partial antinociceptive effects of endomorphins. Nevertheless, the same dose of DAMGO (0.3 g) produced 89%-97% of maximal effects in both nociceptive assays. In contrast, the highest tested dose of endomorphins (i.e., 30 g) produced 73%-84% of maximal effects in the model of inflammatory pain and the same dose of endomorphins produced only 53%-55% of maximal effects in the model of acute pain (Table 1) . Such findings may suggest that DAMGO is more effective in vivo than endomorphins, and that endomorphins' relative efficacy may range between 53% and 84%, depending on the intensity and modality of the nociceptive stimulus. This study is the first using both in vivo and in vitro measurements together to demonstrate the potential partial agonist actions of endomorphins for antinociception and its findings are consistent with a growing body of evidence indicating that the degree of antinociception produced by an opioid agonist depends on its intrinsic efficacy and the nociceptive stimulus intensity. 31, 32, 34, 35 Antagonist studies verified that i.t. endomorphininduced antinociception was mainly mediated by spinal -opioid receptors in rats (Figs. 2 and 4) . The doses for opioid receptor antagonists, naltrexone, naltrindole, and nor-binaltorphimine, used herein were able to produce selective functional antagonism for -, ␦-, and -opioid receptors, respectively. [27] [28] [29] [30] Lack of effects of naltrindole and nor-binaltorphimine against i.t. endomorphin-induced antinociception suggested that the antinociceptive effects of i.t. endomorphins were independent from spinal ␦-and -opioid receptors. In addition, NLX treatment produced similar degrees of parallel rightward shifts of the concentration-response curve for DAMGO-and endomorphin-stimulated [ 35 S]GTP␥S binding in the spinal cord and thalamic membranes ( Table 2) . Such a finding also supports the notion that the -opioid receptor is the key mediator for i.t. endomorphin-induced antinociception at the level of the receptor-G protein in the rat spinal cord. Interestingly, mouse studies indicated that i.t. or intracerebroventricular administration of endomorphin-2 increased the release of dynorphin A 1-17 which subsequently acted on -opioid receptors to produce antinociception. 18, 36 Although a -opioid receptor antagonist, nor-binaltorphimine, did not antagonize the antinociception produced by i.t. endomorphins in the present study, Concentration-response curves of agonist were determined in the absence or presence of an antagonist, naloxone (NLX). Shown are mean Ϯ sem from three independent experiments and each were conducted in duplicate. See Table 2 for other details.
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The duration of antinociception produced by i.t. endomorphins was shorter than that of i.t. DAMGO (i.e., 20 vs 45 min) against acute nociceptive stimulus. Studies have shown that endomorphins are vulnerable to enzymatic cleavage and several enzymes participate in the enzymatic degradation of endomorphins. [37] [38] [39] Interestingly, endomorphin-1 seems more resistant to enzymatic degradation than endomorphin-2 in vivo. 40 However, most studies and the present study did not find a significant difference in the duration between i.t. endomorphin-1-and endomorphin-2-induced antinociception. 15, 16, 36, 41 It is worth noting that the duration of i.t. DAMGO-induced itch/scratching (i.e., 3-4 h) in monkeys is much longer than i.t. DAMGO-induced itch/ scratching and antinociception (Ͻ1 h) in rodents. [42] [43] [44] It is possible that the enzymatic degradation pathway of endomorphins may be different or/and slower in the primate cerebrospinal fluid, and it will be valuable to further investigate the duration and magnitude of antinociception and itch/scratching by i.t. endomorphins in primates.
This study demonstrated that i.t. administration of endomorphins produced antinociceptive effects against acute and inflammatory nociceptive stimuli in rats. More importantly, both in vivo and in vitro measurements together validated that endomorphin-1 and -2 are partial agonists selectively acting at the spinal -opioid receptors. Studies determining DAMGO-and endomorphinstimulated [ 35 S]GTP␥S binding in spinal cord and thalamic membranes are valuable because they provide a pharmacological explanation for the spinal actions of i.t. DAMGO and endomorphins. In particular, it supports the use of the GTP␥S binding assay for exploring and predicting the efficacy of opioid compounds on antinociception against the high intensity of nociceptive stimuli. The pharmacological properties of endomorphins in terms of the receptor binding selectivity and efficacy are unique because other discovered endogenous opioid peptides are not selective for any specific opioid receptor type. 45, 46 This study provides a sound pharmacological basis for studying newly developed endomorphin analogs that may have longer duration of action or/and higher intrinsic efficacy in the future.
